Alpha IVF Group PATMI grows 23.6% to RM15.1 million in 2Q25
• 2Q25 revenue higher by 12.2% to RM43.2 million, mainly driven by Malaysia operations
• Foreign patient base strengthens in 2Q25, led by Indonesia and China; accounts for 71.2% of Malaysia operations revenue
KUALA LUMPUR, Malaysia, 21 January 2025 – Leading fertility care specialist, Alpha IVF Group Berhad (“Alpha IVF Group”, “the Group”, “阿儿法国际辅助生殖集团”, Bloomberg: ALPHA MK, Bursa Ticker: 0303) delivered another strong quarter, with net profit attributable to shareholders (PATMI) of RM15.1 million for the second quarter ended 30 November 2024 (2Q25), up 23.6% from RM12.2 million in the previous year’s same quarter, attributed to higher demand from foreign patients.
Capitalizing on unabated demand for fertility treatment services, the Group reported an increase of 12.2% in revenue to RM43.2 million in 2Q25, compared to RM38.5 million in the previous year.
Malaysia’s operations continued to be the primary revenue contributor, generating RM38.0 million or 87.8% of the Group’s total revenue, with the balance derived from its Singapore operations. The contribution of foreign patients to Malaysia’s operations grew substantially to a revenue of RM27.0 million or 71.2% in 2Q25, up from RM17.4 million or 57.2% in 2Q24, with Indonesia and China driving the growth.
In 2Q25, Indonesian patients contributed the most to Alpha IVF Group’s revenue, accounting for RM15.1 million or 34.9%. At the same time, China patients were the fastest growth segment for the Group, with revenue surging four folds to RM8.1 million in 2Q25, compared to RM2.0 million in the same quarter last year. Meanwhile, local patients remain the second largest revenue contributor for the Group, with RM10.9 million or 25.2%, followed by China patients.
“We are pleased to deliver another good quarter, driven by an increasing demand for our fertility services, particularly from foreign patients. Our focus remains sharp on executing market expansion strategies for FY2025, building on the momentum we have ramped up with our recent regional development. Looking ahead, we are confident in our continued growth prospects. With the broadening of our
services in both existing and new markets, we are well positioned to further strengthen our local and regional footprints.”
Dato’ Dr Colin Lee Soon Soo (拿督 李顺树医生)
Group Managing Director, Alpha IVF
In line with the strong quarterly results, the Group’s revenue for the six months ended 30 November 2024 (1H25) increased by 7.6% to RM86.2 million from RM80.1 million in the previous year. At the same time, 1H25 PATMI rose 16.4% to RM29.5 million from RM25.3 million previously.
On the expansion outlined during the Initial Public Offering (IPO) last year, Dato Dr Colin Lee said, “Our growth plans are proceeding as planned. Recently, the Group even launched a new second sales representative office in Guangzhou, which began operations in early January, following the successful opening of our first sales office in Shanghai last September.”
“Beyond China, we are further expanding our presence in Southeast Asia region with the establishment of a full-fledged IVF centre in the Philippines and our first satellite clinic in Indonesia, tapping into these rapidly growing markets. These initiatives are in line with our strategic goal to become a regional IVF leader.”
